Back to Search
Start Over
Biogen Idec and Elan enrol first patient in large, well-controlled head-to-head study of multiple sclerosis treatments
- Source :
- Chemical Business Newsbase. March 25, 2010
- Publication Year :
- 2010
-
Abstract
- Biogen Idec and Elan Corp plc announced enrolment of the first patient in a global Phase IIIb, randomised, rater-blinded, active-controlled study designed to evaluate switching to Tysabri (natalizumab) from Copaxone [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- Chemical Business Newsbase
- Publication Type :
- News
- Accession number :
- edsgcl.222540000